SSY Group Wins China Approval for Bumetanide Bulk Drug

SSY Group ( (HK:2005) ) has provided an announcement.

SSY Group Limited has secured approval from China’s National Medical Products Administration for its Bumetanide bulk drug, enabling its use in the production of market-ready preparations. The product is a loop diuretic indicated for a wide range of conditions, including edema linked to heart failure and renal or hepatic dysfunction, as well as hypertension and several electrolyte and fluid balance disorders.

The approval expands SSY Group’s injectable and systemic therapy portfolio and reinforces its position in China’s hospital-focused pharmaceutical market. The new registration is expected to support broader clinical adoption of Bumetanide-based treatments, enhancing the group’s product mix in cardiovascular and renal care and potentially strengthening its competitive standing with prescribers and institutional buyers.

The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited is a pharmaceutical company engaged in developing, manufacturing and supplying active pharmaceutical ingredients and related preparations. The group focuses on hospital and clinical treatments in China, with products that address cardiovascular, renal, hepatic and other systemic conditions, aligning its portfolio with high-demand therapeutic areas in the domestic healthcare market.

YTD Price Performance: -13.43%

Average Trading Volume: 8,064,233

Technical Sentiment Signal: Sell

Current Market Cap: HK$7.23B

See more insights into 2005 stock on TipRanks’ Stock Analysis page.